Bioxytran, Inc. · OTC:BIXT
Bioxytran — Investor Presentation (December 2022)
32 slides from Bioxytran's investor presentation, Dec 14, 2022
Slide 1: Corporate Overview
Bi .XyTran Corporate Overview MIKE SHEIKH | mike.sheikh@bioxytraninc.com | (509) 991-0245
Slide 2: Forward Looking Statement
Bio.XyTran Forward Looking Statement This Descriptive Presentation (the “Presentation") has been prepared by Bioxytran, Inc (the “Company”) and recipients are not entitled to rely on the accuracy or completeness of the Presentation. Statistical information contained in this Presentation is based on
Slide 3: Living with Viruses
Living with Viruses Should we embrace COVID-19 Infections 95.7 million COVID-19 Deaths 1.07 million HIV Positive 1.2 million Respiratory Syncytial Virus (RSV) 2.1 million (under 5yrs) Viral Conjunctivitis 5.0 million Long Covid Over 20% of worlds cases (1 in 5) Bi .XyTran Statistics are unacceptable
Slide 4: Mission Statement
Bio. XyTran Mission Statement Bioxytran is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design.
Slide 5: COVID is Over? Why Invest?
BioXyTran’ COVID is OVER — — Why Invest? a > @ No One No One No One President Says Masking Testing Distancing “its over” COVID Has ¢ Easy indication to prove efficacy p d Fact (viral elimination 3 days) ropaganca or Facts * Label expansion likely (platform * CDC no longer reports daily infections (o
Slide 6: What to Look for in a Biotech
Bio.XyTran What to Look for in a Biotech y Yy Horton International inva Attributes of a Successful Biotech ——————— ~ a . — | Nihil dhcmliat cl ee —— = Management — Regulatory Experience wane = Magic — Science AS tae Biotech - Key to success ee GRIT DAILY Press Releases 7 Enepise + Defining a Success
Slide 7: Key Leadership in Galectin Science
Bio.XyTran Key Leadership in Galectin Science BM) Yale 4,000+ Journal Articles on David Platt PhD, CEO, CSO, Chairman medRyxiv © Carbohydrate chemistry expert, founded ees four publicly traded companies, raised oo sscummunen ga Target Receptors $150m in public markets, created $1B in plovtatiny mdon
Slide 8: Management
Management David Platt PhD, CEO, CSO, Chairman Carbohydrate chemistry expert, founded four publicly traded companies, raised $150m in public markets, created $1B in shareholder value, and led development of two drugs. Ola Soderquist CPA, MSA, MBA, CFO >30 years multi-industry financial experience. M
Slide 9: Technology Overview
Bio.XyTran Technology Overview ProLectin Rx — Glycovirology BXT-25 — Hypoxia & Degenerative Diseases ; Ischemia: Virology: + Stroke * Covid-19 i + Alzheimer ° Influenza - Dementia * Conjunctivitis * Traumatic Brain Injury * RSV i Anemia ¢ Other virologic diseases Long term symptoms resulting from vi
Slide 10: Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z
Bio.XyTran Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z Conditions and diseases in which a role for Gal-3 has been postulated Aa Bb Cc Dd Ee Ff Gg Hh Ti] Asthm Blood test Cerebrat HIV Infectio infarction copa aaa bbb cee ddd fff 999 hhh iii Jj Kk LI Mm Nn Oo Pp Qq Juvenile Idiop
Slide 11: ProLectin Rx Glycovirology
BioXyTran ProLectin Rx Glycovirology
Slide 12: ProLectin-Rx Galectin Antagonist Platform
Bio.XyTran ProLectin-Rx Galectin Antagonist Platform Ep @ Versatile Tested (Phase 2*) Mutation agnostic No toxicity therapeutic Reduction of viral load to undetectable levels 7 days cA 8 No Expected Efficient Limitations Eliminate contagion *Galectin approach to lower covid transmission - Drug Devel
Slide 13: Patients Treated With Galectin Antagonist Experienced Reductions In Viral Load
Bio.XyTran Patients Treated With Galectin Antagonist Experienced Reductions In Viral Load Viral Load Vs. Time in Treated Patients 7.00 6.00 5.00 4.00 3.00 < 50 copies/ul. 2.00 1.00 Viral Load (Log10(average(N1+N2) Copies/mL)) 0.00 3 5 Time (days) +Galectin Antagonist use in Mild Cases of SARS-CoV-2
Slide 14: PCR Test Data (Blinded)
BioXyTran PCR Test Data (Blinded) Cycle Threshold (Ct) values are used to assess Prolectin-M Clinical Trial Results infectivity of the patient using a nasal pharyngeal test. Blinded Data n=34 Lower values are a proxy for higher viral loads and increased infectivity. Values over 29 are considered PCR
Slide 15: PCR Test Phase Data
Bio.XyTran PCR Test Phase 2 Data Day 3 — 14 out of 17 were PCR negative (88%) . Day 7 - 17 out of 17 were PCR negative (100%) ProLectin-M Ct Values n=34 Unblinded Data n=34 -— . No toxicity signals Randomized 1:1 Double Blind Placebo Controlled Trial Percentage of COVIO-19 Patients PCR Negative Ct V
Slide 16: Elimination of Viral Rebound
Bio.XyTran Elimination of Viral Rebound There were no rebounds within 14 Paxlovid rebound was common after day 10 days UnBlinded Data | ‘Source: FDA analysis, Figure 2. SARS-CoV-2 RNA levels in NP swabs among Paxlovid treated subjects > > ; Pr. ‘ with or without SARS-CoV-2 amino acid substitutions d
Slide 17: Galectin Antagonists Tags Virus For Elimination
Bio.XyTran Galectin Antagonists Tags Virus For Elimination Theoretical Mechanism of Action CH: Virus Galectin Antagonist A TA XxX HsC ? s rria "te: T & x x “~sS re AoeXe Liver Filtration Human Cells Copyright © Bioxytran 2022. All rights. Version 3.12.12 a
Slide 18: Treatment
Treatment Combination Bio.XyTran End-to-End Solution ProLectin-M ProLectin-l ProLectin-A ProLectin-F Oral Intravenous Intravenous Intravenous Stage | Stage II Stage Ill Stage IV (early infection) (pulmonary phase) (hyperinflammation) (long hauler) > e exes i if > Ww n . . o Viral response ARDS Fibro
Slide 19: Glycovirology Development Pipeline
Glycovirology Development Pipeline Drug & Process Development Cleared Completed Bio.XyTran IND [Product | indication | rectinical | guitMPaion | Phase! | Phase | Phase | hase ly ProLectin-M Oral ProLectin-I Intravenous ProLectin-F Intravenous ProLectin-X Miscellaneous ProLectin-A + Oxysense* Intrave
Slide 20: Therapeutic Approaches for COVID-19
Bio.XyTran Therapeutic Approaches for COVID-19 Immunomodulatory ‘J A a) oe é SI ; ; ? Antiretrovirals Naa (Compete for polymorphism) =s ec Vaccines a i =) —" a Unique Galectin Antagonist — Oral/IV Polysaccharide . — fae - ) a It's not a vaccine, nor an antiretroviral drug XS a > Oxygenation Y 4 (Ven
Slide 21: Competitive Landscape
Competitive Landscape Oral COVID-19 Therapeutics Bio.XyTran Mutagenesis via RdRp — forced mutations induced apoptosis Molnupiravir Paxlovid Tollovir Tempol Ensovibep (intravenous) Merck Pfizer Todos Medical Adamis Molecular Parnters/ Novartis 3CL protease inhibitor — Antiviral & Immune sensitization
Slide 22: BXT-25 — Hypoxia & Degenerative Diseases
BioXyTran BXT-25 — Hypoxia & Degenerative Diseases
Slide 23: Solution: BXT-25 an Oxygen Bridge
Bio.XyTran Solution: BXT-25 an Oxygen Bridge BXT-25 polymer ¢ BXT-25 is a hemoglobin-based polymer; 5,000 times smaller than a red blood cell * It can be used both in Ischemic and Hemorrhagic - Stroke * ¢ It can penetrate a blood-clot and reach the brain within 3 minutes ¢ Reduction of average Time-
Slide 24: How It Works? BXT-25
Bio.XyTran How It Works? BXT-25 — Stabilized Oxygen-carrying Protein Single O, * Delivered as an IV solution molaciile * Universally compatible with all blood types Non-immunogenic Low viscosity Stable at room temperature 3-year shelf-life in liquid formulation Erythrocyte Hemoglobin Extended shelf-
Slide 25: Degenerative Disease/Hypoxia Development Pipeline
Bio.XyTran Degenerative Disease/Hypoxia Development Pipeline Completed ma} Planned Treatment/Device Ie Preclinical Phase IV rocess Dvip BXT-101 Cancer Metastasis NASH BXT-102 + Cirrhosis — Fibrosis BXT.251+ cee Meee Oxysense reservation age — Organ monitoring Stroke BXT-25 + Ischemic —_—) Hemorrhagi
Slide 26: Commercialization & Targets
Commercialization & Targets Bio.XyTran
Slide 27: Clinical Trial Strategy
Bio.XyTran Clinical Trial Strategy Completed m=} Planned ProLectin-M Prolectiel Drug & Process Pre-clinical fees roLectin- Development Studies | . Drug & Process | Pre-clinical | Phase || Phase ProLectin-F Development Studies | Il ProLectin-A / BXT-25 Drug & Process Development Pre-clinical Studies
Slide 28: Use of Proceeds
Bio.XyTran Use of Proceeds Current Round ProLectin-M ProLectin- ProLectin-F ProLectin-Rx* Estimated Project Cost in thousands USD $ 2,700 $ 1,650 $ 1,000 $ 5,350 Development & GMP : - : : Pre-Clinical 100 150 150 400 IND Submission 150 200 200 550 Clinical Trials 2,000 1,000 500 3,500 G&A 450 300 15
Slide 29: Commercialization & IP Strategy
Commercialization & IP Strategy ag Licensing Intellectual Property (IP) ¢ Three (3) issued international patents * One (1) issued US patent * One (1) provisional US patent Partnership ¢ Additional applications to strengthen our IP position are ongoing* * Future patents to be filed at commercializati
Slide 30: Comparables
Bio.XyTran Comparables ‘Roche to pay Atea $350M for ex- COVID-19 Antivirals U.S. rights to COVID-19 antiviral Erne | !) NOVARTIS Bmw ee Merck inks $425M Oncolmmune Novartis Signs an Option and buyout to bag COVID-19 drug License Agreement with Molecular Partners to Develop Two DARPin Crees Therapies
Slide 31: Big Pharma Licensing Targets
Bio. XyTran Big Pharma Licensing Targets Virology Oncology Immunology Respiratory Inflammation THERAPEUTIC AREAS Neuroscience Cardiovascular Hematology Stroke IDEAL PLATFORM DRUG + AbbVie — Oncology, Neuroscience, Immunology, Virology FOR MANY BIG PHARMAS + Allergan — Neuroscience, Ophthalmology, Ga
Slide 32: 2"4 Ave., Suite
Bio.XyTran 75 2"4 Ave., Suite 605 Needham MA, 02494 (617) 454-1199 www.bioxytraninc.com info@bioxytraninc.com Mike Sheikh mike.sheikh@bioxytraninc.com (509) 991-0245 Copyright © Bioxytran 2022. All rights. Version 3.12.12 +.